RIPK1 and diabetes mellitus: While it is increasingly acknowledged that diabetes is an autoinflammatory condition and its complications stem from a prolonged low-grade inflammatory state, the development of drugs targeting RIPK1 and RIPK3 to alleviate diabetic complications remains inadequate.